With 0.12 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.47 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $1.13 whereas the lowest price it dropped to was $1.0. The 52-week range on MYNZ shows that it touched its highest point at $10.56 and its lowest point at $0.92 during that stretch. It currently has a 1-year price target of $14.00. Beta for the stock currently stands at 0.31.
Price Performance and Earnings:
Three-month performance dropped to -32.12% while six-month performance fell -43.43%. The stock lost -74.07% in the past year, while it has lost -86.51% so far this year. EPS is expected to grow by 59.64% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -52.02%.
Float and Shares Shorts:
At present, 5.41 million MYNZ shares are outstanding with a float of 5.34 million shares on hand for trading. On 2025-11-14, short shares totaled 0.26 million, which was 475.0 higher than short shares on 1760486400. In addition to Mr. Guido Baechler as the firm’s CEO & Executive Director, Mr. William J. Caragol CPA serves as its CFO & Senior VP.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With MYNZ analysts setting a high price target of 14.0 and a low target of 14.0, the average target price over the next 12 months is 14.0. Based on these targets, MYNZ could surge 1150.0% to reach the target high and rise by 1150.0% to reach the target low. Reaching the average price target will result in a growth of 1150.0% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$10.84 being high and -$10.84 being low. For MYNZ, this leads to a yearly average estimate of -$10.84.
